Research AppraisalRandomised Controlled Trial

Lignin-Regulated Amphiphilic Janus Membrane for Eco-Friendly Electronic Skin

ACS sensorsHe, Yuan, Ye, Haichuan, Li, Cuihuan et al.26 June 2026DOI

Clinical Snapshot

35CEBM
Evidence: InsufficientRandomised Controlled Trial

PICO Framework

P — PopulationNot a clinical population study; the 'population' is the material system — lignin-derived amphiphilic Janus membranes (LAJM) intended for wearable pressure-sensing applications on human skin, with incidental human subject testing for vital-sign monitoring demonstrations
I — InterventionLignin-regulated amphiphilic Janus membrane (LAJM)-based pressure sensor fabricated via electrospinning with sulfonation and fluorination modifications to create hydrophilic-hydrophobic gradients enabling unidirectional water transport
C — ComparatorImplicit comparison to conventional electronic skin materials and non-Janus membrane configurations; no formal control group or head-to-head clinical comparator is defined
O — OutcomesPrimary: pressure sensing sensitivity (kPa⁻¹), operational range (kPa), response/recovery time (ms); Secondary: unidirectional water transport, biocompatibility, antibacterial efficacy, antioxidant properties, continuous vital-sign monitoring (radial pulse waveforms), voice pattern discrimination, motion trajectory mapping

Bottom Line

This paper describes a technically innovative lignin-derived amphiphilic Janus membrane pressure sensor with impressive laboratory-measured performance characteristics, including high sensitivity (23.97 kPa⁻¹) and rapid response dynamics (22 ms). The integration of moisture management, antibacterial properties, and pressure sensing in a bio-derived, sustainable material represents genuine scientific novelty in the materials engineering field. However, from a clinical evidence perspective, this study provides no actionable information for healthcare practitioners. It is a bench-level proof-of-concept with no clinical trial design, no defined patient population, no statistical rigour, no validated biocompatibility testing, and no comparison against existing clinical monitoring standards. The human demonstrations described appear to be informal feasibility tests rather than structured clinical evaluations. Claims regarding utility in 'AI-driven healthcare diagnostics' and 'intelligent wound care systems' are speculative and unsupported by the presented evidence. Clinicians and health technology assessment bodies should regard this as early-stage materials science research (TRL 3–4) requiring extensive preclinical safety validation, regulatory engagement with the TGA, and properly designed clinical trials before any consideration of clinical adoption. The CEBM evidence level for clinical application is Level 5 (expert opinion/bench research).

Evidence: Insufficient

Key Findings

  • P Value: Not reported

  • Effect Size: Not applicable in clinical terms; engineering metric only — sensitivity 23.97 kPa⁻¹ (no comparator group provided for effect size calculation)

  • Primary Outcome: Pressure sensing sensitivity of 23.97 kPa⁻¹ in the 0–20 kPa range, with an extended operational range of 0–200 kPa

  • Nnt Or Sensitivity: No diagnostic accuracy metrics reported; clinical sensitivity/specificity for any health monitoring application not calculated. Response time: 22 ms; recovery time: 31 ms. These are engineering performance parameters, not clinical diagnostic statistics.

  • Confidence Interval: Not reported

Clinical Application

Clinical feasibility is highly premature. Significant barriers remain: (1) scale-up from laboratory electrospinning to reproducible manufacturing; (2) regulatory approval as a medical device; (3) integration with validated data acquisition and clinical decision-support systems; (4) demonstration of diagnostic accuracy in patient populations; (5) health economic evaluation. Current technology readiness level (TRL) is estimated at TRL 3–4 (proof of concept demonstrated in laboratory). In Australia, any wearable device intended for vital-sign monitoring or wound care would require TGA registration as a medical device under the Therapeutic Goods Act 1989, likely classified as Class IIa or Class III depending on intended use and risk profile. The device would need to meet ARTG inclusion requirements and comply with essential principles for safety and performance. PBS listing for consumable components would require PBAC evaluation demonstrating clinical and cost-effectiveness — entirely undemonstrated at this stage. RACGP guidelines for chronic disease monitoring and wound care management would need to be considered in any future clinical trial design. The eco-friendly lignin sourcing may align with Australian sustainability frameworks but does not confer clinical approval. No Australian-specific data exist. Currently not applicable to any defined clinical population. Potential future populations include patients requiring continuous vital-sign monitoring (e.g., cardiac arrhythmia surveillance, respiratory monitoring in COPD or sleep apnoea), wound care patients, and sports medicine/rehabilitation settings — but only after rigorous clinical validation.

Abstract

Eco-friendly electronic skin fabricated from sustainable natural materials represents a pivotal technology for advancing healthcare and sports-oriented wearable electronics, yet balancing comfort and electronic functionality remains challenging due to inadequate moisture management. Herein, we report an eco-friendly lignin-regulated amphiphilic Janus membrane (LAJM)-based pressure sensor that synergistically integrates unidirectional water transport with exceptional sensing performance. Through sulfonation and fluorination modifications of lignin fractions with distinct hydrophilic and hydrophobic properties, we engineer an electrospun layer with controlled hydrophobic-hydrophilic gradients, enabling unidirectional water transport while maintaining a dry and comfortable microenvironment. Moreover, LAJM demonstrates notable biocompatibility, antibacterial efficacy, and antioxidant properties, positioning it as a promising candidate for intelligent wound care systems. The LAJM-based pressure sensor achieves integrated sensing capabilities through its hierarchical structure, exhibiting a high sensitivity of 23.97 kPa-1 in the 0-20 kPa range, an extended operational range (0-200 kPa), and ultrafast response dynamics (22 ms response/31 ms recovery). These metrics enable robust continuous monitoring of vital signs (e.g., radial pulse waveforms), discrimination of voice patterns, and precise motion trajectory mapping under dynamic conditions. This technological breakthrough in lignin valorization establishes a scalable platform for next-generation breathable epidermal electronics, with transformative implications for AI-driven healthcare diagnostics and adaptive human-machine interfaces.

References

  1. 1.He, Y., Ye, H., Li, C., Li, H., Hu, Y., Miao, G., You, T., Chen, S., & Xu, F. (2026). Lignin-regulated amphiphilic Janus membrane for eco-friendly electronic skin. ACS Sensors. Advance online publication. https://doi.org/10.1021/acssensors.6c00358
Share:XLinkedIn

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service